Amundi
PCVX icon

Amundi’s Vaxcyte PCVX Stock Holding History

Amundi’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Sell
10,003
-2,955
-23% -$160K ﹤0.01% 1592
2026
Q1 		$753K Buy
12,958
+7,868
+155% +$427K ﹤0.01% 1382
2025
Q4 		$235K Buy
+5,090
New +$228K ﹤0.01% 1718
2025
Q2 		– Sell
-343,512
Closed -$10.5M – 2040
2025
Q1 		$10.5M Sell
343,512
-63,416
-16% -$5.07M ﹤0.01% 821
2024
Q4 		$33M Sell
406,928
-27,864
-6% -$2.77M 0.01% 639
2024
Q3 		$48.6M Sell
434,792
-7,516
-2% -$677K 0.02% 551
2024
Q2 		$33.7M Buy
442,308
+139,951
+46% +$9.53M 0.01% 610
2024
Q1 		$18.3M Sell
302,357
-27,431
-8% -$1.9M 0.01% 715
2023
Q4 		$20M Sell
329,788
-13,124
-4% -$682K 0.01% 717
2023
Q3 		$15.8M Buy
342,912
+80,311
+31% +$3.96M 0.01% 746
2023
Q2 		$12.9M Buy
+262,601
New +$12.4M 0.01% 790
2022
Q4 		– Sell
-2,604
Closed -$62K – 1957
2022
Q3 		$62K Hold
2,604
– – ﹤0.01% 1634
2022
Q2 		$64K Buy
+2,604
New +$60.3K ﹤0.01% 1517
2022
Q1 		– Sell
-5,795
Closed -$115K – 1704
2021
Q4 		$115K Buy
+5,795
New +$135K ﹤0.01% 1557

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Amundi's PCVX Position: Q2 2026 in Review

Amundi reduced its Vaxcyte (PCVX) stake by 23% in Q2 2026, selling an estimated $160K and leaving 10,003 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Amundi first reported a position in PCVX in Q4 2021 and has held it in 14 quarters since. The position peaked at $48.6M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Amundi held 10,003 shares of Vaxcyte worth $581K as of Q2 2026.
  • Amundi sold 2,955 Vaxcyte shares in Q2 2026, an estimated $160K.
  • Vaxcyte made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1592 holding.
  • Amundi first reported a position in Vaxcyte in Q4 2021 and has held it in 14 quarters since.
  • Amundi's Vaxcyte position peaked at $48.6M in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.